Improve mAb Purification Process Efficiency With Mixed-Mode Resins

To assess the efficacy of various mAb purification workflows, we purified a CHO cell-derived trastuzumab biosimilar using three distinct protocols: a conventional three-step method and two streamlined two-step approaches. The results demonstrated that the two-step workflows yielded significantly higher quantities of the target mAb while maintaining comparable levels of purity. Moreover, these simplified methods exhibited a markedly superior capacity for removing leached Protein A. Importantly, the removal of host cell proteins and DNA was comparable across all three workflows, indicating that the reduction in processing steps did not compromise the overall quality of the purified mAb.